01 11Adcetris
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 468
2018 Revenue in Millions : 387
Growth (%) : 21
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 547
2019 Revenue in Millions : 477
Growth (%) : 15
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 563
2020 Revenue in Millions : 524
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 642
2021 Revenue in Millions : 563
Growth (%) : 14
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 46
2022 Revenue in Millions : 0
Growth (%) : Acquired from Seagen
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 698
2022 Revenue in Millions : 641
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,089
2023 Revenue in Millions : 56
Growth (%) : 1,845
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 851
2023 Revenue in Millions : 695
Growth (%) : 22
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 253
2015 Revenue in Millions : 242
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 357
2016 Revenue in Millions : 270
Growth (%) : 32
